Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antineoplastic agent
anthracycline antibiotic |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:ATCCode |
L01DB02
|
| gptkbp:CASNumber |
20830-81-3
|
| gptkbp:chemicalFormula |
C27H29NO10
|
| gptkbp:color |
red
|
| gptkbp:derivedFrom |
gptkb:Streptomyces_peucetius
|
| gptkbp:discoveredBy |
gptkb:Federico_Arcamone
|
| gptkbp:discoveredIn |
1963
|
| gptkbp:drugClass |
antineoplastic agents
|
| gptkbp:excretion |
urine
bile |
| gptkbp:hasUNII |
80168379AG
|
| https://www.w3.org/2000/01/rdf-schema#label |
daunomycin
|
| gptkbp:IUPACName |
(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(hydroxyacetyl)-8,10-dihydro-7H-tetracene-5,12-dione
|
| gptkbp:listedOn |
gptkb:WHO_Model_List_of_Essential_Medicines
|
| gptkbp:mechanismOfAction |
DNA intercalation
topoisomerase II inhibition |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
527.52 g/mol
|
| gptkbp:PubChem_CID |
30323
CHEBI:28497 DB00694 |
| gptkbp:sideEffect |
nausea
hair loss cardiotoxicity myelosuppression |
| gptkbp:synonym |
gptkb:daunorubicin
|
| gptkbp:usedFor |
treatment of acute lymphoblastic leukemia
treatment of acute myeloid leukemia |
| gptkbp:bfsParent |
gptkb:daunorubicin
|
| gptkbp:bfsLayer |
7
|